chizyburger

[TimAlerts] CLRB 08:50 AM EST, 01/24/2017 (MT Newswires) -- Cellectar Biosciences (CLRB), an oncology-focused biotechnology company, has been granted a U.S. patent covering the method of use for its lead compound, CLR 131, as well as CLR 125, to treat cancer. Shares of Cellectar Biosciences have surged more than 15% in pre-market trading. The patent, granted by the United States Patent and Trademark Office (USPTO), covers the use of CLR 131 for the potential treatment of a broad range of malignant solid tu

chizyburger

[TimAlerts] $ETRM finally gave a good win for me in at 2.30 out at 23.67 for $711 profit... first big win for newbie me... slowly learning.. thanks to you Tim and the whole team for teaching us...

Received 2 Karmas
Page
of 2